Frequency Therapeutics Announces Positive Phase 1/2 Trial Results for Hearing Restoration Drug
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical…
Read More
Decibel Therapeutics Appoints New Chief Medical Officer and COO
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…
Read MorePharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics
Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…
Read More
Frequency Therapeutics Completes $42 Million Series B Financing
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced earlier this month that it has closed $42 million in Series B financing. The latest funding round for the company, which is seeking to create a new class of drugs based on small molecule stimulation of dormant stem cells within the body, brings the total capital raised…
Read More
Sound Pharmaceuticals Advances Phase 2 Clinical Trial in Cystic Fibrosis Patients to Prevent Hearing Loss
SEATTLE, WASHINGTON AND CHARLESTON, SOUTH CAROLINA — Sound Pharmaceuticals, a Seattle-based biotech firm, announced that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with the company’s oral drug, SPI-1005, is aimed to prevent and treat ototoxicity in patients with Cystic Fibrosis undergoing intravenous (IV) tobramycin for the…
Read More
Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders. According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will…
Read More
Spiral Therapuetics Receives $3.7M Investment to Advance Treatment of Hearing Loss and Inner Ear Disorders
SAN FRANCISCO, CALIFORNIA — According to a news report out this week, early-stage pharmaceutical company Spiral Therapeutics has received a $3.7 million investment towards the development of treatments for hearing loss and other inner ear related disorders. The Series A funding round was led by Camden Partners Nexus, a biomedical-focused venture fund, and Savoir Capital. Spiral Therapeutics’ initial…
Read MoreFrequency Therapeutics Completes Enrollment in Safety Trial for Hearing Restoration Drug Candidate, FX-322
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced this week the completion of enrollment in the single dose safety trial to evaluate FX-322, the company’s leading drug candidate for hearing restoration. The randomized, double-blind, placebo-controlled trial will be assessing the safety of a single dose of FX-322 given by intratympanic administration in adult patients with…
Read More
Decibel Therapeutics Obtains Exclusive License to Develop and Commercialize ORC-13661 from Oricula Therapeutics
BOSTON & SEATTLE — Boston-based biotech firm, Decibel Therapeutics, announced this week that it has obtained “an exclusive, worldwide license to the development and commercialization of ORC-13661” from Oricula Therapeutics for the prevention of hearing loss and balance disorders due to the use of aminoglycoside antibiotics. As part of the agreement with Decibel, Oricula will…
Read More
Auris Medical Receives FDA Guidance for Investigative Drug to Treat Sudden Sensorineural Hearing Loss
ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced today that it has received feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA) related to the development plan and regulatory pathway for AM-111, the company’s investigational treatment for sudden sensorineural hearing loss. The meeting had been conducted at the request of…
Read More